vida: extract claims from 2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025

- Source: inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
 challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
-related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
 supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
 reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
 ---
@@ -53,3 +53,10 @@ Meta-analysis of 14 studies (n=5,262,278) shows pooled AUDIT score reduction of
 **Source:** Qeadan F et al., Addiction 2025
 
 Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US health systems found GLP-1 RA prescriptions associated with 40% lower opioid overdose rates (IRR 0.60, 95% CI 0.43-0.83) in OUD cohort and 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) in AUD cohort over 24-month follow-up. Effects consistent across T2DM, obesity, and combined subgroups. This is the largest-scale human data on GLP-1 for opioid outcomes, though observational design creates substantial healthy user bias concerns (patients receiving GLP-1 are more healthcare-engaged, financially able, and motivated). The consistency across subgroups (whether prescribed for diabetes or obesity) reduces some confounding concern. Published in Addiction (Wiley) with formal commentary noting need for prospective RCTs.
+
+
+## Extending Evidence
+
+**Source:** Grigson PS et al., Addiction Science & Clinical Practice 2025
+
+NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractory OUD (n=200, patients already on buprenorphine/methadone who continue illicit use). Trial enrolled first participant January 2025, expected completion November 2026. Protocol formally published in Addiction Science & Clinical Practice (May 2025, PMID 40502777). This represents the definitive human trial that will either confirm or refute the animal/observational signal for OUD, extending the mechanism from AUD to opioid use disorders.

inbox/archive/health/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md

@@ -7,9 +7,12 @@ date: 2025-05-01
 domain: health
 secondary_domains: []
 format: trial-protocol
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-25
 priority: low
 tags: [GLP-1, semaglutide, OUD, opioid-use-disorder, clinical-trial, addiction, reward-circuit, VTA-dopamine]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content